Objective:To evaluate the risk of malignancy indices(RMI-1 and RMI-2) based on serum CA125,menopausal status,and ultrasound score for forecast the patients with ovarian tumors.Methods:The sensitivity,Specificity,posit...Objective:To evaluate the risk of malignancy indices(RMI-1 and RMI-2) based on serum CA125,menopausal status,and ultrasound score for forecast the patients with ovarian tumors.Methods:The sensitivity,Specificity,positive predictive value of serum CA125,ultrasound scores and menopausal status,separately and combined into the RMI-1 andRMI-2,for differential diagnosis of ovarian tumors.Results:Benign ovarian tumors 76 cases and ovarian cancers 37 cases were randomly measured.The RMI-1 at a cut off value of 100 gave a sensitivity of 81.1%,specificity of 93.4%.A sensitivity of 78.3%,specificity of 96.0% were given at a cut off value of 125.RMI-2 gave a sensitivity of 81.0%,specificity of 89.5% and 78.3%,90.8% respectively.For all cut off values between 50 and 200,RMI-1 performerd better than that of RMI-2.RIM was more accurate than menopausal status,ultrasound score,and serum CA125 separately in diagnosing ovarian tumors,and was comparable with other scoring systems.Conclusions:RMI-1 is more reliable in discrimination benign and malignant ovarian tumors than that of RMI-2.RMI is a simple,practical and reliable method which can be used in gynecologic clinics.展开更多
目的：探讨血清糖类抗原125（CA125）及CA125联合CA199、CA153、癌胚抗原（CEA）检测在卵巢癌诊断中的意义。方法：采用化学发光微粒子免疫检测法测定71例卵巢癌患者、10例卵巢交界性肿瘤患者和42例卵巢良性肿瘤患者血清中CA125、CA199...目的：探讨血清糖类抗原125（CA125）及CA125联合CA199、CA153、癌胚抗原（CEA）检测在卵巢癌诊断中的意义。方法：采用化学发光微粒子免疫检测法测定71例卵巢癌患者、10例卵巢交界性肿瘤患者和42例卵巢良性肿瘤患者血清中CA125、CA199、CA153和CEA的含量,阳性诊断标准分别为：CA125〉35 k U/L,CA199〉37 k U/L,CA153〉30 k U/L,CEA〉5μg/L。结果：在单项肿瘤标记物中,CA125的阳性率最高（84.5%）,敏感度、特异度和准确度指标平稳。在不同的联合检测方案中CA199、CA153与CA125联合检测方案最优,较CA125单项检测敏感度和准确度均有提高。晚期卵巢癌（Ⅲ～Ⅳ期）患者的CA153、CA125含量高于早期卵巢癌（Ⅰ～Ⅱ期）患者（P〈0.001）。结论：CA199、CA153、CEA与CA125在卵巢癌鉴别诊断中均有一定价值,并可以根据CA153、CA125含量判断患者卵巢癌的分期,CA199、CA153与CA125联合检测是诊断卵巢癌较为理想的标记物组合。展开更多
文摘Objective:To evaluate the risk of malignancy indices(RMI-1 and RMI-2) based on serum CA125,menopausal status,and ultrasound score for forecast the patients with ovarian tumors.Methods:The sensitivity,Specificity,positive predictive value of serum CA125,ultrasound scores and menopausal status,separately and combined into the RMI-1 andRMI-2,for differential diagnosis of ovarian tumors.Results:Benign ovarian tumors 76 cases and ovarian cancers 37 cases were randomly measured.The RMI-1 at a cut off value of 100 gave a sensitivity of 81.1%,specificity of 93.4%.A sensitivity of 78.3%,specificity of 96.0% were given at a cut off value of 125.RMI-2 gave a sensitivity of 81.0%,specificity of 89.5% and 78.3%,90.8% respectively.For all cut off values between 50 and 200,RMI-1 performerd better than that of RMI-2.RIM was more accurate than menopausal status,ultrasound score,and serum CA125 separately in diagnosing ovarian tumors,and was comparable with other scoring systems.Conclusions:RMI-1 is more reliable in discrimination benign and malignant ovarian tumors than that of RMI-2.RMI is a simple,practical and reliable method which can be used in gynecologic clinics.
文摘目的：探讨血清糖类抗原125（CA125）及CA125联合CA199、CA153、癌胚抗原（CEA）检测在卵巢癌诊断中的意义。方法：采用化学发光微粒子免疫检测法测定71例卵巢癌患者、10例卵巢交界性肿瘤患者和42例卵巢良性肿瘤患者血清中CA125、CA199、CA153和CEA的含量,阳性诊断标准分别为：CA125〉35 k U/L,CA199〉37 k U/L,CA153〉30 k U/L,CEA〉5μg/L。结果：在单项肿瘤标记物中,CA125的阳性率最高（84.5%）,敏感度、特异度和准确度指标平稳。在不同的联合检测方案中CA199、CA153与CA125联合检测方案最优,较CA125单项检测敏感度和准确度均有提高。晚期卵巢癌（Ⅲ～Ⅳ期）患者的CA153、CA125含量高于早期卵巢癌（Ⅰ～Ⅱ期）患者（P〈0.001）。结论：CA199、CA153、CEA与CA125在卵巢癌鉴别诊断中均有一定价值,并可以根据CA153、CA125含量判断患者卵巢癌的分期,CA199、CA153与CA125联合检测是诊断卵巢癌较为理想的标记物组合。
